Adma Biologics Inc (NASDAQ: ADMA) kicked off on Monday, down -4.52% from the previous trading day, before settling in for the closing price of $17.15. Over the past 52 weeks, ADMA has traded in a range of $3.06-$21.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 73.26%. While this was happening, its average annual earnings per share was recorded 471.15%. With a float of $225.20 million, this company’s outstanding shares have now reached $226.06 million.
Let’s determine the extent of company efficiency that accounts for 624 employees. In terms of profitability, gross margin is 45.96%, operating margin of 25.42%, and the pretax margin is 11.86%.
Adma Biologics Inc (ADMA) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Adma Biologics Inc is 3.38%, while institutional ownership is 77.89%. The most recent insider transaction that took place on Sep 09 ’24, was worth 166,189. In this transaction Director of this company sold 9,000 shares at a rate of $18.47, taking the stock ownership to the 153,941 shares. Before that another transaction happened on Sep 09 ’24, when Company’s Director proposed sale 9,000 for $16.26, making the entire transaction worth $146,340.
Adma Biologics Inc (ADMA) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported 0.01 earnings per share (EPS), higher than consensus estimate (set at -0.01) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 471.15% per share during the next fiscal year.
Adma Biologics Inc (NASDAQ: ADMA) Trading Performance Indicators
Take a look at Adma Biologics Inc’s (ADMA) current performance indicators. Last quarter, stock had a quick ratio of 2.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.55. Likewise, its price to free cash flow for the trailing twelve months is 57.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.14, a number that is poised to hit 0.13 in the next quarter and is forecasted to reach 0.66 in one year’s time.
Technical Analysis of Adma Biologics Inc (ADMA)
Looking closely at Adma Biologics Inc (NASDAQ: ADMA), its last 5-days average volume was 8.94 million, which is a jump from its year-to-date volume of 3.63 million. As of the previous 9 days, the stock’s Stochastic %D was 21.46%. Additionally, its Average True Range was 1.09.
During the past 100 days, Adma Biologics Inc’s (ADMA) raw stochastic average was set at 59.59%, which indicates a significant increase from 12.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.90% in the past 14 days, which was higher than the 67.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.70, while its 200-day Moving Average is $10.29. However, in the short run, Adma Biologics Inc’s stock first resistance to watch stands at $17.01. Second resistance stands at $17.66. The third major resistance level sits at $18.12. If the price goes on to break the first support level at $15.90, it is likely to go to the next support level at $15.44. Should the price break the second support level, the third support level stands at $14.79.
Adma Biologics Inc (NASDAQ: ADMA) Key Stats
The company with the Market Capitalisation of 3.82 billion has total of 231,809K Shares Outstanding. Its annual sales at the moment are 258,220 K in contrast with the sum of -28,240 K annual income. Company’s last quarter sales were recorded 107,190 K and last quarter income was 32,060 K.
